AUTL
Autolus Therapeutics plc
Halal Rating :
Last Price
$2.22
Last updated:
Market Cap
-
7D Change
-3.48%
1 Year Change
-61.39%
Company Overview
Industries
Exchange
Next Earnings Date
Autolus Therapeutics plc is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer. The company's primary focus is on developing AUTO1, its lead candidate for the treatment of acute lymphoblastic leukemia (ALL). The company uses its proprietary programming modules to engineer T cells with enhanced therapeutic properties.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| March 31, 2024 | $10.09m | $68.12m | - | $19.27m | 0.00% | 28.29% |
Company Impact
Help us evaluate Autolus Therapeutics plc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.